New England Journal of Medicine has published the results of E4599, a Phase III clinical study showing that combination therapy of Avastin (bevacizumab, manufactured by Genentech, Inc.), paclitaxel, and carboplatin significantly improved overall survival in lung cancer patients. (More …)
Latest Tips RSS
-
TargetingTumors.com
-
TargetingTumors.com
Today, the U.S. Food and Drug Administration (FDA) has approved Avastin or bevacizumab (made by Genentech) for combination treatment with carboplatin and paclitaxel in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, non-small cell lung cancer (NSCLC). Avastin is often referred by oncologists as a “targeted agent” because its target is a growth factor receptor that has been observed to become abnormal in cancers and tumors. (More …)